FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
• Median overall survival for cM0 CRPC patients ranged from 44 to 74 months
• Median progression-free survival from 9 to 22 months
o None of the studies link PFS to OS
• Median metastasis-free survival from 16 to 53 months
o One study linked MFS as a surrogate for OS
• Most common form of metastasis was bone metastasis, which was associated with an increased risk of skeletal-related events (SREs)
• Quality-of-life was widely reported to decrease upon metastasis, driven by increased pain and SREs
• Higher healthcare costs associated with metastatic CRPC were attributable to physician visits and treating bone-metastasis-related complications.
The authors make a case for the importance of therapies in this space, as it could delay the onset of metastasis and thereby lead to economic benefits for healthcare delivery systems.
Indeed, at GU ASCO this year, two major Phase III studies assessing enzalutamide and apalutamide for this very disease space are reporting final results. With promising oncologic outcomes, they may be the beginning of a trend to earlier initiation of systemic therapies for cM0 CRPC.
Speaker: Neal Shore, MD
Co-Authors: Gershwinder Rai, Karim Fizazi, Laura Wilson, Lin Zhan
Institution(s): Carolina Urologic Research Center, Myrtle Beach, SC; QuintilesIMS, Reading, United Kingdom; Gustave Roussy Institute of Oncology, University of Paris-Sud, Villejuif, France; Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ
Written by: Thenappan Chandrasekar, MD, Clinical Fellow, University of Toronto, Twitter: @tchandra_uromd at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, February 8-10, 2018 - San Francisco, CA